Dr. Rick Xu, M.D., Ph.D.

Dr. Rick Xu, Chief Medical Officer of Oricell Therapeutics Inc, began his career in the pharmaceutical industry in 1991.  Since then, he has  worked for Sterling Winthrop, Pfizer, Hoffman-La Roche, and Genentech. He played a pivotal role in the design and development of the PEGSYS and Long Acting Filgrastim, two multi-billion dollars products. Throughout his professional career, he has been primarily involved in global drug development, filing numerous Investigational New Drug (IND) applications and New Drug Applications (NDAs), and has built extensive experience in oncology, central nervous system, virology, and anti-infectious diseases. In March 2024, he joined Oricell Therapeutics as Chief Medical Officer, where he leads the clinical development activities of multiple CAR-T projects aimed at treating hematological malignancies and solid tumors. Prior to joining Oricell, he was the Chief Medical Officer of InnoCare Pharma, where he successfully developed Orelabrutinib, a best-in-class BTK inhibitor, bringing it from IND to NDA in just two years.  Additionally, he has been a venture partner of Quan Capital. Dr. Xu’s expertise encompasses various ImmunoOncology targets and cell/gene therapeutic treatments.  He frequently receives invitations to present at national and international conferences and has served as and advisor and consultant for numerous scientific institutions and non-profit professional organizations worldwide.